Related references
Note: Only part of the references are listed.Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer
Karin Milde-Langosch et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis
Christian R. Loehberg et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Prognostic Value of Breast Cancer Subtypes, Ki-67 Proliferation Index, Age, and Pathologic Tumor Characteristics on Breast Cancer Survival in Caucasian Women
N. Lynn Ferguson et al.
BREAST JOURNAL (2013)
Correlation between Ki67 and Breast Cancer Prognosis
Konstantinos Kontzoglou et al.
ONCOLOGY (2013)
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Elisabeth Luporsi et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Advances in Breast Cancer - Looking Back over the Year
D. Lueftner et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2012)
Biomarkers in Breast Cancer - An Update
M. Schmidt et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2012)
Breast Cancer 2012-New Aspects
H. -C. Kolberg et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2012)
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
Mohammed A. Aleskandarany et al.
BREAST CANCER RESEARCH (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011)
Michael Untch et al.
BREAST CARE (2011)
St. Gallen 2011: Summary of the Consensus Discussion
Michael Gnant et al.
BREAST CARE (2011)
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
Jack Cuzick et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
Bhumsuk Keam et al.
BREAST CANCER RESEARCH (2011)
Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67
Shinichiro Kashiwagi et al.
BREAST CANCER RESEARCH (2011)
Personalized treatment of early-stage breast cancer: Present concepts and future directions
Nadia Harbeck et al.
CANCER TREATMENT REVIEWS (2010)
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi et al.
LANCET ONCOLOGY (2010)
Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients
Folkward G. Wiesner et al.
BREAST (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Recent advances in systemic therapy New diagnostics and biological predictors of outcome in early breast cancer
Catherine Oakman et al.
BREAST CANCER RESEARCH (2009)
Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
Jocelyne Jacquemier et al.
BREAST CANCER RESEARCH (2009)
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients
R. Stuart-Harris et al.
BREAST (2008)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical application of the 70-gene profile: The MINDACT trial
Fatima Cardoso et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
Giuseppe Viale et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Understanding the molecular basis of histologic grade
M. Ignatiadis et al.
PATHOBIOLOGY (2008)
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
Pratyaksha Wirapati et al.
BREAST CANCER RESEARCH (2008)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E. de Azambuja et al.
BRITISH JOURNAL OF CANCER (2007)
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
M Colozza et al.
ANNALS OF ONCOLOGY (2005)
Proliferation marker Ki-67 in early breast cancer
A Urruticoechea et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Preoperative systemic treatment: prediction of responsiveness
M Colleoni et al.
BREAST (2003)
Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer
L Assersohn et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer
CD Archer et al.
BRITISH JOURNAL OF CANCER (2003)
Ki-67 expression in breast carcinoma - Its association with grading systems, clinical parameters, and other prognostic factors - A surrogate marker?
H Trihia et al.
CANCER (2003)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Correlation between MIB-1 and other proliferation markers -: Clinical implications of the MIB-1 cutoff value
F Spyratos et al.
CANCER (2002)
Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer
A Bottini et al.
BRITISH JOURNAL OF CANCER (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
